Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
XKLS:0155'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.98 Med: -0.57 Max: 3.13
Current: 1.21
During the past 13 years, the highest Debt-to-EBITDA Ratio of Malaysian Genomics Resource Centre Bhd was 3.13. The lowest was -4.98. And the median was -0.57.
XKLS:0155's Debt-to-EBITDA is ranked better than 64.04% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs XKLS:0155: 1.21
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Malaysian Genomics Resource Centre Bhd Debt-to-EBITDA Related Terms
Malaysian Genomics Resource Centre Bhd Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Malaysian Genomics Resource Centre Bhd Debt-to-EBITDA Chart
Malaysian Genomics Resource Centre Bhd Annual Data
XKLS:0155 vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Malaysian Genomics Resource Centre Bhd's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Malaysian Genomics Resource Centre Bhd Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Malaysian Genomics Resource Centre Bhd's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Malaysian Genomics Resource Centre Bhd's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Malaysian Genomics Resource Centre Bhd (XKLS:0155) has a Debt-to-EBITDA of 0.20 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Malaysian Genomics Resource Centre Bhd. According to the industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #41 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 36%.
Is Malaysian Genomics Resource Centre Bhd's Debt-to-EBITDA too high?
Malaysian Genomics Resource Centre Bhd's current Debt-to-EBITDA is 0.20. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Malaysian Genomics Resource Centre Bhd's value of 0.20 is 91.3% below this industry median. Based on the distribution chart, Malaysian Genomics Resource Centre Bhd ranks #41 out of 114 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Malaysian Genomics Resource Centre Bhd has a GF Score™ of 46/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Malaysian Genomics Resource Centre Bhd's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Malaysian Genomics Resource Centre Bhd ranks #41 out of 114 companies for Debt-to-EBITDA. This puts Malaysian Genomics Resource Centre Bhd in the upper half of its industry. The industry median Debt-to-EBITDA is 2.31. Malaysian Genomics Resource Centre Bhd's value of 0.20 is 91.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Malaysian Genomics Resource Centre Bhd's current Debt-to-EBITDA of 0.20 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Malaysian Genomics Resource Centre Bhd. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Malaysian Genomics Resource Centre Bhd's current Debt-to-EBITDA is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malaysian Genomics Resource Centre Bhd stock overvalued right now?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd (XKLS:0155) is currently considered Fairly Valued. The stock's GF Value™ is RM0.31, compared to a current price of RM0.32 — trading 3.2% above its estimated fair value. The current Debt-to-EBITDA is 0.20 and 91.3% below the Medical Diagnostics & Research industry median of 2.31. Malaysian Genomics Resource Centre Bhd's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Malaysian Genomics Resource Centre Bhd (XKLS:0155), the current Debt-to-EBITDA is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Malaysian Genomics Resource Centre Bhd (XKLS:0155) Overvalued in 2026?
Based on GuruFocus' analysis, Malaysian Genomics Resource Centre Bhd stock appears to be overvalued.
The current stock price of RM0.32 is trading 3.2% above its estimated GF Value™ of RM0.31.
GuruFocus considers Malaysian Genomics Resource Centre Bhd to be Fairly Valued.
Key valuation signals for XKLS:0155:
Debt-to-EBITDA: 0.20
GF Value™: RM0.31 vs. price of RM0.32 (3.2% above fair value)
Industry Position: 91.3% below the Medical Diagnostics & Research median (#41 of 114)
No single metric tells the full story. See the XKLS:0155 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Malaysian Genomics Resource Centre Bhd is a Malaysia-based company. The company's principal activities include enabling personalized and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services, as well as investment holding. It offers genome sequencing and analysis (GSA) services and genetic screening services (GSS). The group offerings include precision genetic screening, project-based analysis, and high-quality cell therapy and cosmeceutical products. The reportable segments of the Group derive their revenue from the provision of personalised and precision medicine through genetics, genomics, immunotherapy, and biopharmaceutical services within the healthcare segment.
46GF Score
Get the complete analysis for XKLS:0155
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0155 has been successfully added to your 
